PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC
Advanced Science · 2026-06 · 13 (35)
DOI: 10.1002/advs.202507647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.01.2026. Verfasst von Zheyu Shao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, CD4-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Fundamental Research Funds for the Central Universities.
Themen: Mobilisation
Abstract (Originalsprache)
Tissue‐resident memory CD4+ T cells (CD4+ TRMs) are pivotal in immune responses during inflammation and infection, yet their phenotype and function within the tumor microenvironment (TME) remain elusive. Here, we delineated CD4+ TRMs in non‐small cell lung cancer (NSCLC) using CD103 and CD69 as defining markers and demonstrated that their transcriptional and phenotypic profiles closely resembled those observed in murine models. Tumor‐infiltrating CD4+ TRMs exert helper antitumor effects by secreting the chemokine XCL1 to recruit conventional type 1 dendritic cells (cDC1s), facilitating antigen presentation and priming cytotoxic T lymphocyte responses. Mechanistically, we identified the costimulatory molecule JAML as essential for CD4+ TRM‐mediated cDC1 mobilization. Compared with their counterparts in normal lung tissue, tumor‐infiltrating CD4+ TRMs exhibited elevated expression of immune checkpoint molecules, indicating a dysfunctional state, accompanied by significantly reduced XCL1 expression. PD‐1 signaling within the NSCLC TME suppressed JAML expression—an effect reversible by PD‐1 blockade—while the administration of a JAML agonist further enhanced the antitumor efficacy of PD‐1 inhibitors in tumor‐bearing mice. Clinically, the presence of XCL1‐secreting CD4+ TRMs positively correlated with favorable clinical outcomes and enhanced responses to anti‐PD‐1 immunotherapy in NSCLC patients. Our findings reveal a critical role for JAML in facilitating CD4+ TRM‐mediated cDC1 mobilization within the NSCLC TME and highlight the translational potential of targeting CD4+ TRMs to enhance the efficacy of immune checkpoint blockade therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
- Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
ORCID-Profile: Pin Wu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Fundamental Research Funds for the Central Universities
- Young Investigator Award from Institut Mérieux, the Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang
- Beijing Xisike Clinical Oncology Research Foundation
- National Key R&D Program of China
- Joint Funds of the National Natural ScienceFoundation of China
- National Key Research and Development Program of China
Zitieren
APA
Shao, Z., Liu, Q., Xin, Z., Zhou, Z., Lin, M., Chen, D., Hao, Z., Chen, Y., Wu, W., Zhang, S., Chen, X., Xu, X., Li, J., Lin, W., Lu, Y., Wu, D., & Wu, P. (2026). PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC. Advanced Science, 13(35). https://doi.org/10.1002/advs.202507647
Vancouver
Shao Z, Liu Q, Xin Z, Zhou Z, Lin M, Chen D, et al. PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC. Advanced Science. 2026;13(35). doi:10.1002/advs.202507647
BibTeX
@article{Shao2026,
author = {Shao, Zheyu and Liu, Qinyuan and Xin, Zhongwei and Zhou, Zhiyao and Lin, Mingjie and Chen, Di and Hao, Zhixing and Chen, Yongyuan and Wu, Wenxuan and Zhang, Shuyang and Chen, Xiaoke and Xu, Xia and Li, Jinfan and Lin, Wei and Lu, Yuhao and Wu, Dang and Wu, Pin},
title = {PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {35},
doi = {10.1002/advs.202507647}
}
EUVIMED